News from the FDA/CDC

Most cigarette smokers attempt to quit without evidence-based techniques


 

FROM MMWR

More than half of cigarette smokers have received advice to quit from a health care professional, but less than a third used medication or counseling in their cessation attempt, according to investigators from the Centers for Disease Control and Prevention.

In 2015, just over 57% of adult smokers said that a health care professional had advised them to quit in the past year. Of those who tried to quit, 29% used medication such as nicotine patches or gum, varenicline, or bupropion; 7% used counseling (including a stop-smoking clinic, class, or support group and a telephone help line); and 31% used counseling and/or medication, the investigators reported (MMWR 2017;65[52]:1457-64).

Cessation interventions among adult cigarette smokers, 2015
Data from the 2015 National Health Interview Survey show that cigarette smokers who were white (60%) or of multiple races (70%) were the most likely to have a health professional tell them to quit, while Asians (34%) and American Indians/Alaska natives (38%) were the least likely. Whites were most likely to use counseling and/or medication (34%) and Hispanics were least likely (19%), although the rate for American Indians/Alaska Natives was not reported because of a small sample size or large margin of error, they noted.

With the overall cessation rate at less than 10%, “it is critical for health care providers to consistently identify smokers, advise them to quit, and offer evidence-based cessation treatments, and for insurers to cover and promote the use of these treatments and remove barriers to accessing them,” the investigators wrote.

Recommended Reading

Insomnia in young men boosts cardiovascular and cerebrovascular risk
MDedge Psychiatry
Insomnia severity more pronounced in older Hispanics
MDedge Psychiatry
GERD and sleep disorders often go hand in glove
MDedge Psychiatry
Flumazenil effective in refractory hypersomnolence
MDedge Psychiatry
FDA updates warning label for systemic fluoroquinolones
MDedge Psychiatry
FDA: New labeling warns against combining opioids, benzodiazepines
MDedge Psychiatry
MRI measurements reveal effects of sleep deprivation
MDedge Psychiatry
Depression drops COPD medication adherence
MDedge Psychiatry
FDA eases mental health warnings in smoking cessation drugs’ labels
MDedge Psychiatry
Survey shines new light on weighty comorbidity burden in adult atopic dermatitis
MDedge Psychiatry